PL380866A1 - Zastosowanie smilageniny do leczenia choroby Parkinsona - Google Patents

Zastosowanie smilageniny do leczenia choroby Parkinsona

Info

Publication number
PL380866A1
PL380866A1 PL38086699A PL38086699A PL380866A1 PL 380866 A1 PL380866 A1 PL 380866A1 PL 38086699 A PL38086699 A PL 38086699A PL 38086699 A PL38086699 A PL 38086699A PL 380866 A1 PL380866 A1 PL 380866A1
Authority
PL
Poland
Prior art keywords
alzheimer disease
treating alzheimer
derivatives intended
steroid sapogenins
sapogenins
Prior art date
Application number
PL38086699A
Other languages
English (en)
Other versions
PL207723B1 (pl
Inventor
Zongqin Xia
Yaer Hu
Ian Rubin
Jonathan Brostoff
Brian Whittle
Weijun Wang
Phil Gunning
Original Assignee
Phytopharm Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9806513.9A external-priority patent/GB9806513D0/en
Priority claimed from GBGB9905275.5A external-priority patent/GB9905275D0/en
Application filed by Phytopharm Plc filed Critical Phytopharm Plc
Publication of PL380866A1 publication Critical patent/PL380866A1/pl
Publication of PL207723B1 publication Critical patent/PL207723B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8964—Anemarrhena
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8965—Asparagus, e.g. garden asparagus or asparagus fern
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/944—Acetylcholine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
PL380866A 1998-03-26 1999-03-26 Zastosowanie smilageniny do leczenia choroby Parkinsona PL207723B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9806513.9A GB9806513D0 (en) 1998-03-26 1998-03-26 Membrane-bound receptors
GBGB9905275.5A GB9905275D0 (en) 1999-03-08 1999-03-08 Treatment of conditions associated with membrane-bound receptors and their function
PCT/GB1999/000951 WO1999048507A2 (en) 1998-03-26 1999-03-26 Steroidal saponins for treating alzheimer's disease

Publications (2)

Publication Number Publication Date
PL380866A1 true PL380866A1 (pl) 2001-08-13
PL207723B1 PL207723B1 (pl) 2011-01-31

Family

ID=26313369

Family Applications (3)

Application Number Title Priority Date Filing Date
PL380866A PL207723B1 (pl) 1998-03-26 1999-03-26 Zastosowanie smilageniny do leczenia choroby Parkinsona
PL99343423A PL195897B1 (pl) 1998-03-26 1999-03-26 Zastosowanie smilageniny
PL99343508A PL343508A1 (en) 1998-03-26 1999-03-26 Smilagenin and anzurogenin-d and their use

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL99343423A PL195897B1 (pl) 1998-03-26 1999-03-26 Zastosowanie smilageniny
PL99343508A PL343508A1 (en) 1998-03-26 1999-03-26 Smilagenin and anzurogenin-d and their use

Country Status (27)

Country Link
US (2) US6812213B2 (pl)
EP (3) EP1719512B1 (pl)
JP (4) JP3768100B2 (pl)
KR (6) KR100713311B1 (pl)
CN (3) CN1198622C (pl)
AT (3) ATE337788T1 (pl)
AU (2) AU748138B2 (pl)
BR (2) BR9909110A (pl)
CA (2) CA2325633C (pl)
CY (1) CY1105653T1 (pl)
DE (3) DE69943415D1 (pl)
DK (2) DK1719512T3 (pl)
ES (2) ES2272060T3 (pl)
GB (1) GB2335599B (pl)
HR (2) HRP20000637A2 (pl)
HU (2) HUP0103654A2 (pl)
ID (2) ID26989A (pl)
IL (4) IL138663A0 (pl)
IS (2) IS5637A (pl)
MX (1) MXPA00009437A (pl)
NO (4) NO20004803L (pl)
NZ (1) NZ507355A (pl)
PL (3) PL207723B1 (pl)
PT (1) PT1066042E (pl)
RU (1) RU2297228C2 (pl)
TR (2) TR200002774T2 (pl)
WO (2) WO1999048507A2 (pl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277978B1 (en) 1995-12-22 2001-08-21 University Of Utah Research Foundation KVLQT1—a long QT syndrome gene
AU781810B2 (en) * 1998-03-26 2005-06-16 Phytopharm Plc. Steroidal sapogenins and their derivatives for treating Alzheimer's disease
US20030118673A1 (en) * 1998-03-26 2003-06-26 Zongqin Xia Smilagenin and anzurogenin-D for the treatment of alzheimer's disease
ATE337788T1 (de) * 1998-03-26 2006-09-15 Phytopharm Plc Steroidale saponine zur behandlung der alzheimerischen krankheit
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB2347676A (en) * 1999-03-08 2000-09-13 Phytopharm Plc Screening method
US20010024664A1 (en) * 1999-03-19 2001-09-27 Obukowicz Mark G. Selective COX-2 inhibition from edible plant extracts
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
BR0308788A (pt) * 2002-03-27 2005-01-11 Phytopharm Plc Processos terapĂȘuticos e usos de sapogeninas e seus derivados
KR101130212B1 (ko) * 2002-03-27 2012-04-13 파읎토팜 플엘씚 ì‚ŹíŹêȌ닌 및 ê·ž 유도ìČŽì˜ ìč˜ëٌ ë°©ëȕ 및 ì‚Źìš©ëȕ
PL213697B1 (pl) * 2002-03-27 2013-04-30 Phytopharm Plc Substancje czynne do stosowania w leczeniu chorĂłb, zwlaszcza chorĂłb neurodegeneracyjnych
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
NZ563183A (en) * 2002-03-27 2009-03-31 Phytopharm Plc Therapeutic methods and uses of sapogenins and their derivatives
PL210114B1 (pl) 2002-10-28 2011-12-30 Phytopharm Plc SposĂłb stereospecyficznego wytwarzania 3ÎČ-hydroksy-5ÎČ-H-steroidowych sapogenin
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
GB0409567D0 (en) * 2004-04-28 2004-06-02 Phytopharm Plc Chemical compounds
EP1809298A4 (en) * 2004-10-14 2008-06-18 Univ Georgetown NEUROPROTECTIVE PHARMACEUTICAL SPIROSTENOL COMPOSITIONS
GB0424528D0 (en) 2004-11-05 2004-12-08 Phytopharm Plc Chemical compounds
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513888D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
KR100779179B1 (ko) * 2006-05-19 2007-11-28 충북대학ꔐ 산학협렄닚 토볔ë č의 ë©”íƒ„ì˜Ź ì¶”ì¶œëŹŒì„ 핚유하는 뇌신êČœ 볎혞 또는퇎행성뇌질환 예방 또는 ìč˜ëŁŒì œ
JP2009256243A (ja) * 2008-04-17 2009-11-05 Noevir Co Ltd 保æčżć‰€ă€æŠ—è€ćŒ–ć‰€ă€æŠ—é…žćŒ–ć‰€ă€çšźè†šć€–ç”šć‰€ćŠăłæ©Ÿèƒœæ€§ç”ŒćŁç”„æˆç‰©
WO2009153800A1 (en) 2008-06-17 2009-12-23 Pawan Kumar Goel A novel process for extraction of furostanolic saponins from fenugreek seeds
KR101027384B1 (ko) * 2009-06-29 2011-04-11 에읎디엠읎십음 ìŁŒì‹íšŒì‚Ź 플랫와읎퍌랔레읎드와 와읎퍌아암의 연êČ°ìž„ìč˜
AU2010207597A1 (en) 2009-01-24 2011-08-18 Phytopharm Plc Treatment of neurotrophic factor mediated disorders
BR112013001422A2 (pt) 2010-07-20 2019-09-24 Phytopharm Plc metodo para tratar ou previnir disturbios induzidos por l-dopa, agonista dopamina e/ou acentuador de dopamina em um individuo que necessita dos mesmos, agente, composição, uso de ou mais agentes e metodo para tratar a doença de parkinson
TWI422378B (zh) * 2010-11-18 2014-01-11 Univ Chung Shan Medical äœżç”šè–Żè•·çš‚çŽ äŸ†æ”čć–„èˆ‡ćœç¶“æœŸç—‡ć€™çŸ€æœ‰é—œèŻçš„èȘçŸ„çŒș陷
CN102389438A (zh) * 2011-06-30 2012-03-28 挗äșŹćžˆèŒƒć€§ć­Š 黄èŠȘç”Č苷的ćș”甚
JP5789339B2 (ja) * 2013-01-21 2015-10-07 レゾăƒȘă‚Șæ ȘćŒäŒšç€Ÿ ă‚ąăƒ«ăƒ„ăƒă‚€ăƒžăƒŒç—…ç­‰ă‚’ć«ă‚€ç„žç”Œç–Ÿæ‚ŁăźïŒ‘ïŒŒïŒ’ïŒ•ïœ„ïŒ“âˆ’ïœïœïœ’ïœ’ïœ“ăŒé–ąäžŽă™ă‚‹æČ»ç™‚è–ŹćŠăłæČ»ç™‚æł•
DK3194557T3 (da) 2014-09-16 2020-09-21 Roar Holding Llc Energidrikke og andre ernĂŠringstilsĂŠtningsstoffer udledt af agavebaserede spirituosa
KR101777920B1 (ko) * 2015-07-27 2017-09-14 ìžŹë‹šëČ•ìž 지늄형 바읎였 시슀템 ì„€êł„ 및 합성 ì—°ê”Źë‹š ì§„ì„žë…žì‚ŹìŽë“œ f1을 포핹하는 ì•„ë°€ëĄœìŽë“œ í”ŒëŒíŹ 제거용 ìĄ°ì„±ëŹŒ
CN105168785A (zh) * 2015-10-08 2015-12-23 æč–ćŒ—æ°‘æ—ć­Šé™ą 侀种æČ»ç–—é˜żć°”èŒšæ”·é»˜ç—…çš„äž­èŻćˆ¶ć‰‚ćŠćˆ¶ć€‡æ–čæł•
EP3572085A1 (en) 2018-05-25 2019-11-27 Neuro-Sys Synergestic combination composition comprising a steroidal saponin, a first polyphenolic compound and optionnaly a second polyphenolic compound
CN108514603B (zh) * 2018-06-28 2021-12-28 äœłæœšæ–Żć€§ć­Š 侀种æČ»ç–—ćŒșç›Žćž‹ćž•é‡‘æŁźç—…çš„äž­èŻç»„ćˆç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•
KR102028730B1 (ko) 2019-05-22 2019-10-04 (ìŁŒ)큎래시슀 집속쎈음파 Ʞ술을 읎용한 지ëȘš ì¶”ì¶œëŹŒì˜ ì œìĄ°ë°©ëȕ 및 ìŽëĄœë¶€í„° 수득된 지ëȘš ì¶”ì¶œëŹŒ
CN110859849A (zh) * 2019-12-11 2020-03-06 ć€§èżžćŒ»ç§‘ć€§ć­Š è–Żè“Łçš‚è‹·ćœšćˆ¶ć€‡ćž•é‡‘æŁźç—…äżæŠ€èŻç‰©äž­çš„ćș”甚
US11788574B2 (en) 2021-08-13 2023-10-17 Rimgard Sweden AB Anti-theft locking bolt assembly

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794362A (fr) * 1972-01-22 1973-07-23 Merck Patent Gmbh Sulfates hydrosolubles de sterine
US3929769A (en) * 1972-05-19 1975-12-30 Ciba Geigy Corp Process for the manufacture of steroid epoxides
CA985172A (en) * 1972-10-06 1976-03-09 Dushan M. Dvornik Compositions and methods for reducing blood cholesterol
DE2416978A1 (de) * 1974-04-08 1975-10-09 Degussa Arzneimittel mit dem hauptsapogenin der helleborus-arten als wirkstoff
LU81256A1 (fr) * 1979-05-15 1980-12-16 Oreal Composition cosmetique capillaire notamment pour le lavage et/ou le demelage des cheveux,a base d'un extrait de plantes contenant des saponosides
JPS5855500A (ja) * 1981-09-25 1983-04-01 Tokiwa Yakuhin Kogyo Kk ïŒ‘ïŒ–âˆ’ăƒ‡ăƒ’ăƒ‰ăƒ­ăƒ—ăƒŹă‚°ăƒăƒŽăƒ­ăƒłăźèŁœé€ æł•
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4562250A (en) * 1982-09-13 1985-12-31 Regents Of The University Of Minnesota Steroidal glycosides produced by Yucca tissue culture
US4546097A (en) * 1983-11-04 1985-10-08 The United States Of America As Represented By The Department Of Health And Human Services Saponin-based polyether polyols, pharmaceutical compositions and a method of using same
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
US5017562A (en) * 1987-02-11 1991-05-21 Regents Of The University Of Minnesota Crystalline saponin-containing complex
DE3838716A1 (de) * 1988-11-15 1990-05-17 Kanoldt Arzneimittel Gmbh Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie
ATE188036T1 (de) * 1990-01-18 2000-01-15 Cura Nominees Pty Ltd Glykoalkaloide
DE4122706C1 (pl) * 1991-07-09 1993-03-04 Steigerwald Arzneimittelwerk
US5252729A (en) * 1991-10-23 1993-10-12 Schering Corporation Extraction of compounds from plant materials using supercritical fluids
US5244887A (en) * 1992-02-14 1993-09-14 Straub Carl D Stanols to reduce cholesterol absorption from foods and methods of preparation and use thereof
BR9306619A (pt) * 1992-06-26 1998-12-08 Pfizer GlicosĂ­deos esteroidais para o tratamento da hipercolesterolemia
DE4303214A1 (de) * 1993-02-04 1994-08-11 Wolfgang Marks Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone
AU6274394A (en) * 1993-02-23 1994-09-14 Pharmakon Usa, Inc. Therapeutic herbal composition
CN1092992A (zh) * 1993-03-29 1994-10-05 äž­ć›œç§‘ć­Šé™ąæČˆé˜łćș”甚生态研究所 æé«˜è„‘ćŠŸèƒœçš„èŻç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•
CN1052636C (zh) * 1993-03-29 2000-05-24 äž­ć›œç§‘ć­Šé™ąæČˆé˜łćș”甚生态研究所 æ–‡ć† æžœć­çš„é†‡æć–ç‰©ćœšćˆ¶ć€‡æČ»ç–—æ™șćŠ›äœŽäž‹çš„èŻç‰©äž­çš„ćș”甚
WO1994025479A1 (en) * 1993-04-28 1994-11-10 Pfizer Inc. Spirostanyl glycosidal crystalline monohydrate
CN1033754C (zh) * 1993-05-31 1997-01-08 äžŠæ”·çŹŹäșŒćŒ»ç§‘性歊 çŸ„æŻçš‚ç”™ć…ƒäœœäžșćˆ¶ć€‡ÎČ肟䞊è…ș箠撌Mèƒ†çą±ć—äœ“ćŒć‘è°ƒèŠ‚èŻçš„ç”šé€”ćŠć…¶ćˆ¶æł•
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
CA2180149A1 (en) * 1993-12-28 1995-07-06 Michael Paul Deninno Steroidal glycosides
CA2180148A1 (en) * 1993-12-28 1995-07-06 Michael Paul Deninno Hypocholesterolemic agents
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US5840740A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
PL318937A1 (en) * 1994-08-30 1997-07-21 Pfizer Spirostanyloglycoside crystals
US5807834A (en) * 1994-09-20 1998-09-15 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
WO1996038466A1 (en) * 1995-05-29 1996-12-05 Pfizer Inc. Steroidal glycosides
US5847172A (en) * 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5763430A (en) * 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5795885A (en) * 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US5840936A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US5804239A (en) * 1996-07-26 1998-09-08 Nouveau Technologies, Inc. Method and composition for food flavoring
WO1998051302A1 (en) * 1997-05-15 1998-11-19 University Of Washington Composition and methods for treating alzheimer's disease and other amyloidoses
US6156291A (en) * 1997-08-28 2000-12-05 Cv Technologies Inc. Chemical and pharmacological standardization of herbal extracts
CN1131237C (zh) 1997-09-26 2003-12-17 äž­ć›œäșșæ°‘è§Łæ”Ÿć†›ć†›äș‹ćŒ»ć­Šç§‘ć­Šé™ąæ”Ÿć°„ćŒ»ć­Šç ”ç©¶æ‰€ 生䜓皂甙é˜ČæČ»è€ćčŽæ€§ç—Žć‘†çš„ç”šé€”ćŠæ–°çš„ç”Ÿäœ“çš‚ç”™
JP3873097B2 (ja) * 1997-11-06 2007-01-24 ç‹Źç«‹èĄŒæ”żæł•äșșç†ćŒ–ć­Šç ”ç©¶æ‰€ 抗肄æș€ć‰€ćŠăłè„‚èłȘä»ŁèŹæ”č斄所
ATE337788T1 (de) * 1998-03-26 2006-09-15 Phytopharm Plc Steroidale saponine zur behandlung der alzheimerischen krankheit
GB9905275D0 (en) * 1999-03-08 1999-04-28 Phytopharm Ltd Treatment of conditions associated with membrane-bound receptors and their function
US6544566B1 (en) * 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol

Also Published As

Publication number Publication date
IL138663A0 (en) 2001-10-31
ATE314057T1 (de) 2006-01-15
DE69933016T2 (de) 2007-03-29
CN1301166A (zh) 2001-06-27
ATE507834T1 (de) 2011-05-15
EP1066042B1 (en) 2006-08-30
EP1066033B1 (en) 2005-12-28
PL207723B1 (pl) 2011-01-31
AU748138B2 (en) 2002-05-30
MXPA00009437A (es) 2002-05-06
DE69929177D1 (de) 2006-02-02
NO20083993L (no) 2000-09-11
NO20004803L (no) 2000-11-27
KR20090009997A (ko) 2009-01-23
NO20004804L (no) 2000-11-09
KR20070007214A (ko) 2007-01-12
DE69933016D1 (de) 2006-10-12
HUP0101693A2 (hu) 2001-12-28
HK1033903A1 (en) 2001-10-05
RU2004123463A (ru) 2006-01-27
DE69929177T2 (de) 2006-08-24
RU2297228C2 (ru) 2007-04-20
AU3158199A (en) 1999-10-18
DE69943415D1 (de) 2011-06-16
NO20004804D0 (no) 2000-09-26
KR101092050B1 (ko) 2011-12-12
EP1066042A2 (en) 2001-01-10
JP2002507572A (ja) 2002-03-12
PL343423A1 (en) 2001-08-13
CN1209112C (zh) 2005-07-06
CA2325634A1 (en) 1999-09-30
CN1302208A (zh) 2001-07-04
WO1999048482A3 (en) 2000-11-23
HRP20000637A2 (en) 2001-04-30
WO1999048482A2 (en) 1999-09-30
TR200002773T2 (tr) 2001-11-21
JP2004224797A (ja) 2004-08-12
IS5637A (is) 2000-09-25
NO20004803D0 (no) 2000-09-26
JP2003524581A (ja) 2003-08-19
HUP0103654A2 (hu) 2002-02-28
PL343508A1 (en) 2001-08-27
CN1198622C (zh) 2005-04-27
US20060182817A1 (en) 2006-08-17
US20020193317A1 (en) 2002-12-19
WO1999048507A2 (en) 1999-09-30
GB9907100D0 (en) 1999-05-19
EP1719512A3 (en) 2007-04-11
KR100632052B1 (ko) 2006-10-04
HK1091417A1 (en) 2007-01-19
DK1719512T3 (da) 2011-08-15
KR20090007505A (ko) 2009-01-16
WO1999048507A3 (en) 1999-11-25
CA2325633C (en) 2009-01-20
BR9909110A (pt) 2000-12-12
EP1719512B1 (en) 2011-05-04
ES2272060T3 (es) 2007-04-16
CY1105653T1 (el) 2010-12-22
ES2257042T3 (es) 2006-07-16
PL195897B1 (pl) 2007-11-30
GB2335599A (en) 1999-09-29
ATE337788T1 (de) 2006-09-15
KR100713311B1 (ko) 2007-05-04
IL138664A0 (en) 2001-10-31
IS5638A (is) 2000-09-25
EP1719512A2 (en) 2006-11-08
GB2335599B (en) 2001-08-01
JP3768100B2 (ja) 2006-04-19
NZ507355A (en) 2004-02-27
IL138663A (en) 2006-08-01
EP1066033A1 (en) 2001-01-10
JP2004217666A (ja) 2004-08-05
KR20010042205A (ko) 2001-05-25
HUP0101693A3 (en) 2002-08-28
CA2325633A1 (en) 1999-09-30
HRP20000638A2 (en) 2001-04-30
HK1033742A1 (en) 2001-09-21
PT1066042E (pt) 2006-12-29
US6812213B2 (en) 2004-11-02
CN100377714C (zh) 2008-04-02
DK1066042T3 (da) 2006-12-18
KR20070117001A (ko) 2007-12-11
BR9909109A (pt) 2000-12-12
ID26781A (id) 2001-02-08
IL174991A0 (en) 2006-08-20
NO20085251L (no) 2000-11-09
CN1679591A (zh) 2005-10-12
ID26989A (id) 2001-02-22
AU3157499A (en) 1999-10-18
KR20010042190A (ko) 2001-05-25
TR200002774T2 (tr) 2001-06-21

Similar Documents

Publication Publication Date Title
IL138663A0 (en) Steroidal sapogenins and their derivatives for treating alzheimer's disease
IL180972A0 (en) 5-beta-sapogenin and psuedosapogenin derivatives and their use in the treatment of dementia
WO2002079221A3 (en) Sapogenin derivatives, their synthesis and use
WO2001049703A3 (en) Substituted sapogenins and their use
IL164161A0 (en) Therapeutic methods and uses of sapogenins and their derivatives
CA2069483A1 (en) Steroid sulphatase inhibitors
CA2385410A1 (en) Sapogenin derivatives and their use in the treatment of cognitive dysfunction
GB9923078D0 (en) Sapogenin derivatives and their use
ZA200006046B (en) Steroidal sapogenins and their derivatives for treating Alzheimer's disease.
BR0308788A (pt) Processos terapĂȘuticos e usos de sapogeninas e seus derivados
NO20044468L (no) Anvendelse av sapogeniner samt derav ved fremstilling av medikamenter
MY134920A (en) 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia
TW200833344A (en) Therapeutic methods and uses of sapogenins and their derivatives